SII may use Oxford Biomedica's plant to make malaria, flu vaccines

SII is building a future pandemic facility, which will have an annual capacity of 2 bn doses

Serum Institute of India (SII) may make “flu or malaria vaccines” at the Oxford Biomedica facility at Oxbox near Oxford, said SII CEO Adar Poonawalla.

SII had invested in Oxford Biomedica through its subsidiary Serum Life Sciences last year to help fund the development of the plant that was making Covid-19 vaccines then. Speaking with Business Standard, SII CEO Adar Poonawalla said there is a 10-year tie-up with Oxford Biomedica and a potential to manufacture other vaccines at that facility.

“Oxford Biomedica is a listed entity, and they were making Vaxzevria (the Oxford-AstraZeneca vaccine) at that point (when SII invested in it).